Not SBIR involved since the late nineties, in January 2011, the firm then known as Commonwealth Biotechnologies filed for Chapter 11 Bankrupcy Protection. In August 2013 the company merged with a newly formed subsidiary, HedgePath Pharmaceuticals, Inc (OTC:HPPI) - previously trading on NASDAQ. Interseingly, the new entity raised almost exactly to same IPO support as the oirginal firm - $6.1M. HedgePath is a clinical stage biopharmaceutical company, focused primarily on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. The firm is conducting an open-label Phase II (b) clinical trial for studying the effect of SUBA-Itraconazole oral capsules in patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented and proprietary itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble.
